Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
J Med Case Rep ; 12(1): 285, 2018 Oct 05.
Article in English | MEDLINE | ID: mdl-30286805

ABSTRACT

BACKGROUND: It is not unusual for systemic diseases to mimic sepsis and, in any case, the clinician should thoroughly investigate this possibility. CASE PRESENTATION: We present the case of a 21-year-old Greek woman who presented to the Intensive Care Unit of our hospital with severe septic shock - multiple organ failure as a result of a suspected gynecological infection of the ovaries. An immediate improvement of her clinical condition in combination with strong clinical suspicion and negative cultures led to the differential diagnosis of diseases other than sepsis. Based on the results of the biopsies that were obtained by research laparotomy, our patient suffered from primary Burkitt ovarian lymphoma. Her clinical condition improved with supportive treatment and chemotherapy. Chemotherapy is the dominant treatment for Burkitt's lymphoma, while surgery or radiotherapy has no place. CONCLUSIONS: All intensivists should be aware of clinical conditions that mimic sepsis as early diagnosis can lead to appropriate therapy and avoid unnecessary diagnostic tests and antibiotic abuse.


Subject(s)
Antineoplastic Combined Chemotherapy Protocols/administration & dosage , Biopsy/methods , Burkitt Lymphoma , Ovarian Neoplasms , Ovary/pathology , Shock, Septic/diagnosis , Burkitt Lymphoma/pathology , Burkitt Lymphoma/physiopathology , Burkitt Lymphoma/therapy , Diagnosis, Differential , Early Detection of Cancer/methods , Female , Humans , Laparotomy/methods , Multiple Organ Failure/diagnosis , Multiple Organ Failure/etiology , Ovarian Neoplasms/pathology , Ovarian Neoplasms/physiopathology , Ovarian Neoplasms/therapy , Treatment Outcome , Young Adult
2.
APMIS ; 122(1): 68-75, 2014 Jan.
Article in English | MEDLINE | ID: mdl-23656439

ABSTRACT

Evidence from a recent randomized study of our group suggests that intravenous clarithromycin resulted in earlier resolution of ventilator-associated pneumonia. The need to understand the mechanism of action of clarithromycin guided to the study of a model of experimental empyema by multidrug-resistant Pseudomonas aeruginosa in 40 rabbits. Animals were randomized into controls (group A); treatment with clarithromycin (group B); treatment with piperacillin/tazobactam (group C); and treatment with both agents (group D). Pleural fluid was collected at regular time intervals for quantitative culture, estimation of cell apoptosis and of concentrations of tumour necrosis factor-alpha (TNFα). After 7 days, animals were euthanized for estimation of tissue growth. Bacterial growth in the pleural fluid of group D was significantly decreased compared with the other groups on day 5. Lung growth of group D was lower than group A. That was also the case of cytokine stimulation by pleural fluid samples on U937 monocytes. It is concluded that administration of clarithromycin enhanced the antimicrobial efficacy of piperacillin/tazobactam and decreased bacterial growth in the pleural fluid and in tissues. It also attenuated the pro-inflammatory phenomena induced by the ß-lactam.


Subject(s)
Anti-Bacterial Agents/therapeutic use , Clarithromycin/therapeutic use , Empyema, Pleural/drug therapy , Empyema, Pleural/microbiology , Pseudomonas Infections/drug therapy , Pseudomonas Infections/microbiology , Pseudomonas aeruginosa , Adjuvants, Immunologic/administration & dosage , Adjuvants, Immunologic/therapeutic use , Animals , Anti-Bacterial Agents/administration & dosage , Apoptosis/drug effects , Apoptosis/immunology , Clarithromycin/administration & dosage , Disease Models, Animal , Drug Resistance, Multiple, Bacterial , Drug Therapy, Combination , Empyema, Pleural/immunology , Humans , Interleukin-6/biosynthesis , Male , Penicillanic Acid/administration & dosage , Penicillanic Acid/analogs & derivatives , Piperacillin/administration & dosage , Piperacillin, Tazobactam Drug Combination , Pleural Effusion/immunology , Pleural Effusion/microbiology , Pseudomonas Infections/immunology , Pseudomonas aeruginosa/drug effects , Rabbits , Tumor Necrosis Factor-alpha/biosynthesis , U937 Cells
SELECTION OF CITATIONS
SEARCH DETAIL
...